Back to search results

Study on Patients With Autoimmune Podocytopathy (SLIT ABS)

This study is looking at nephrotic syndrome, a kidney condition causing protein in the urine and swelling, which often affects children. While many respond to steroids, some experience relapses or don't respond to standard treatments. Researchers believe that immune system issues, specifically antibodies against a kidney protein called nephrin, might play a role. This study will analyze blood and kidney tissue samples (collected during routine care) from patients with nephrotic syndrome, including those with Minimal Change Disease (MCD), Focal Segmental Glomerulosclerosis (FSGS), and Idiopathic Membranous Nephropathy. The goal is to understand how levels of anti-nephrin antibodies change over time and if they are linked to the disease. You can join if you are a child or adult diagnosed with podocytopathy and nephrotic syndrome. The study plans to enroll 50 participants.

Study design
This interventional study plans to enroll 50 participants of all ages. It will involve analyzing serum and renal tissue samples.
What's involved
You will have serum and renal biopsy material collected as part of your routine clinical care. These samples will be analyzed in a laboratory.
Compensation
Not stated in the trial record.
Follow-up
Your anti-nephrin antibody levels will be analyzed from enrollment through 5 years of follow-up.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07516964

SLIT ABS: Study on Patients With Autoimmune Podocytopathy

Recruiting
NAAges 0–99InterventionalBasic science
Meyer Children's Hospital IRCCS
~50 participants
Updated 2026-04-08 on ClinicalTrials.gov
What's tested:Serum and renal tissue analysis

At a glance

Recruiting sites
1 of 14 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Analysis of anti-nephrin antibody levels
Measured over From enrollment through 5 years of follow-up

Conditions

Nephrotic Syndrome With Edema (Diagnosis)
Minimal Change Nephrotic Syndrome
Focal Segmental Glomerulosclerosis (FSGS)
Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy

Explore related trials

Collapsing GlomerulopathyCongenital Nephrotic Syndrome - Diffuse Mesangial SclerosisFocal Segmental GlomerulosclerosisMembranous GlomerulonephritisMinimal Change Glomerulonephritis

Where it's being run

14 sites across 7 states
Italy8
Minnesota1
Germany1
Firenze1
FIRENZE1
Mexico1
Spain1

Who to contact

Paola Romagnani, MD, PhD
[email protected]
+39 0555662563
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Pediatric and adult patients with a diagnosis of podocytopathy
Patients with nephrotic syndrome and/or histological diagnosis of minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), collapsing glomerulopathy (CG), or diffuse mesangial sclerosis (DMS)
Both newly diagnosed (incident) patients and patients already under follow-up at participating centers
Availability of clinical data from medical records (including paper and/or electronic records, laboratory reports, and discharge summaries)
Availability of biological samples (e.g., blood and/or renal biopsy), if collected as part of routine clinical care
Signed informed consent by the patient or legal guardian (and assent when applicable)

Exclusion

Refusal or inability of the patient, parents, or legal guardian to provide informed consent
Lack of sufficient clinical data or unavailable biological samples required for the study

What this trial measures

  • Analysis of anti-nephrin antibody levelsFrom enrollment through 5 years of follow-up

    Detection of circulating anti-nephrin antibodies in serum by ELISA and localization of antibody binding in renal biopsy tissue using high-resolution confocal and STED microscopy.